BUZZ-Australia's Race Oncology advances on premium placement

Reuters

Dec 09, 2025

BUZZ-Australia's <a href="https://laohu8.com/S/RAC.AU">Race Oncology</a> advances on premium placement

** Shares of Race Oncology RAC.AX rise as much as 10.1% to A$2.94, their largest intraday pct jump since November 17

** Biopharmaceutical firm receives commitments to raise A$3.22 million ($2.13 million) via a placement

** Placement issue price at A$2.83 per share, a 6% premium to stock's last close

** Says funds will be used to advance the commencement of co's HARNESS-1 phase 1 trial for non-small cell lung cancer

** Stock up 109.6% YTD, including the day's moves

($1 = 1.5090 Australian dollars)

(Reporting by Nikita Maria Jino in Bengaluru)

((Nikita.Jino@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590364731"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590364731\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590364731?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 07:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590364731","market":"us","top_or_hot":-1,"title":"BUZZ-Australia's Race Oncology advances on premium placement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's <a href=\"https://laohu8.com/S/RAC.AU\">Race Oncology</a> advances on premium placement</title></head><body><p>** Shares of Race Oncology <span>RAC.AX</span> rise as much as 10.1% to A$2.94, their largest intraday pct jump since November 17</p><p>\n    ** Biopharmaceutical firm <span>receives</span> commitments to raise A$3.22 million ($2.13 million) via a placement\n  </p><p>\n    ** Placement issue price at A$2.83 per share, a 6% premium to stock's last close\n  </p><p>\n    ** Says funds will be used to advance the commencement of co's HARNESS-1 phase 1 trial for non-small cell lung cancer\n  </p><p>\n    ** Stock up 109.6% YTD, including the day's moves\n  </p><p>($1 = 1.5090 Australian dollars)</p><p>(Reporting by Nikita Maria Jino in Bengaluru)</p><p>((Nikita.Jino@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's Race Oncology advances on premium placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's Race Oncology advances on premium placement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-09 07:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's <a href=\"https://laohu8.com/S/RAC.AU\">Race Oncology</a> advances on premium placement</title></head><body><p>** Shares of Race Oncology <span>RAC.AX</span> rise as much as 10.1% to A$2.94, their largest intraday pct jump since November 17</p><p>\n    ** Biopharmaceutical firm <span>receives</span> commitments to raise A$3.22 million ($2.13 million) via a placement\n  </p><p>\n    ** Placement issue price at A$2.83 per share, a 6% premium to stock's last close\n  </p><p>\n    ** Says funds will be used to advance the commencement of co's HARNESS-1 phase 1 trial for non-small cell lung cancer\n  </p><p>\n    ** Stock up 109.6% YTD, including the day's moves\n  </p><p>($1 = 1.5090 Australian dollars)</p><p>(Reporting by Nikita Maria Jino in Bengaluru)</p><p>((Nikita.Jino@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE17Q:1","article_id":"2590364731","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590364731","pubTimestamp":1765238338,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Australia's Race Oncology advances on premium placement** Shares of Race Oncology RAC.AX rise as much as 10.1% to A$2.94, their largest intraday pct jump since November 17. ** Biopharmaceutical firm receives commitments to raise A$3.22 million  via a placement. ** Placement issue price at A$2.83 per share, a 6% premium to stock's last close. ** Says funds will be used to advance the commencement of co's HARNESS-1 phase 1 trial for non-small cell lung cancer","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7067":"生物科技","RAC.AU":"RACE ONCOLOGY LTD"},"translate_title":"BUZZ-澳大利亚Race Oncology在优质配售方面取得进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":0.9},"content_text":"BUZZ-Australia's Race Oncology advances on premium placement** Shares of Race Oncology RAC.AX rise as much as 10.1% to A$2.94, their largest intraday pct jump since November 17\n    ** Biopharmaceutical firm receives commitments to raise A$3.22 million ($2.13 million) via a placement\n  \n    ** Placement issue price at A$2.83 per share, a 6% premium to stock's last close\n  \n    ** Says funds will be used to advance the commencement of co's HARNESS-1 phase 1 trial for non-small cell lung cancer\n  \n    ** Stock up 109.6% YTD, including the day's moves\n  ($1 = 1.5090 Australian dollars)(Reporting by Nikita Maria Jino in Bengaluru)((Nikita.Jino@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}